Clinical Trials Logo

Clinical Trial Summary

The purpose of this project is to determine if reversal of neuromuscular blockade in cardiac surgery patients expedites time to extubation in fast track patients.


Clinical Trial Description

Neuromuscular blocking agents are used as part of most general anesthetics to help facilitate tracheal intubation and optimal surgical conditions (Barish et al). These medications cause universal paralysis of patients while unconscious. After most surgeries where extubation is planned, the standard of care is to "reverse" any residual neuromuscular blockade with either anticholinesterase treatment (specifically neostigmine) or sugammadex. Despite adequate reversal, residual neuromuscular blockade is a common problem seen in the post-anesthetic care unit (PACU). It leads to issues of airway obstruction, hypoxemia, respiratory complications including atelectasis and pneumonia and muscle weakness (Brull et al). The investigators posit that these complications are likely amplified in patients who require post-operative intensive care unit admission. In particular, the investigators hypothesize that cardiac surgery patients are at risk. Elective cardiac surgery patients are routinely admitted to the CVICU still intubated and ventilator-dependent immediately following surgery. The goal of uncomplicated cardiac surgery patients (fast track cardiac surgery patients) is to extubate them within 6 hours of ICU arrival. However, standard of care throughout the US does not include reversal of their neuromuscular blockade. By the time these patients meet extubation criteria, most providers believe that the neuromuscular blockade should have worn off and therefore do not administer reversal (Murphy et al). The investigators hypothesize that residual neuromuscular blockade delays time to extubation and increases respiratory complications in fast track cardiac surgery patients. By administering reversal of neuromuscular blockade in patients with a Train Of Four ratio of <0.9 we anticipate that there will be an increase from 60 to 85% of patients being successfully extubated within 6 hours of arrival to the ICU and a decrease in composite respiratory complications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03574337
Study type Interventional
Source Henry Ford Health System
Contact
Status Withdrawn
Phase Phase 4
Start date August 1, 2018
Completion date August 30, 2018

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04619225 - Cardiac Output and Recovery Time N/A
Recruiting NCT05992090 - Neuromuscular Blockade Monitoring Using Kine-myography vs Electromyography.
Completed NCT02146859 - Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Completed NCT03585400 - Validation of the REPS Prediction Tool
Terminated NCT01678625 - Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade
Completed NCT03417804 - Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Completed NCT03111082 - Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?
Completed NCT04244266 - Observational Study in Bariatric Surgery
Completed NCT02939911 - Residual Neuromuscular Blockade in Pediatric Anesthesia
Completed NCT02660398 - Incidence and Severity of Residual Neuromuscular Blockade Phase 4
Completed NCT03920670 - Comparison of the ToFscan and TetraGraph During Recovery of Neuromuscular Function in the Post Anesthesia Care Unit N/A
Completed NCT01837498 - Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
Completed NCT02213848 - Effect of Calcium Chloride on Recovery From Neuromuscular Blockade N/A
Completed NCT04352140 - Electromyographic and Acceleromyographic Monitoring in Restricted Arm Movement Surgical Setting N/A
Completed NCT04352127 - Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve N/A
Completed NCT04312256 - Thumb vs Great Toe Recovery N/A